INTRODUCTION
============

Endometrial cancer is the most frequently diagnostic malignancy of the female reproductive tract. In the United States, approximately 49,560 cases are diagnosed and about 8,190 women die from the disease each year.[@b1-jcp-18-313] Estrogen-dependent endometrioid carcinoma is the most common type of endometrial cancer. An increased incidence of endometrial cancer has been found in association with prolonged, unopposed estrogen exposure in postmenopausal women. Lately, progesterone therapy has been used as a process to impede the development of endometrial cancer associated with unopposed estrogen in the belief that the combined therapy will prevent the increase of estrogen-induced risk for endometrial cancer.[@b2-jcp-18-313],[@b3-jcp-18-313]

The majority of endometrial cancers are adenocarcinomas, which originate in uterine epithelial cells. The inner layer of the human uterus, the endometrium, consists of heterogeneous cell types that undergo dynamic changes in response to the ovarian steroid hormones estrogen and progesterone to support embryo development and implantation. Estrogen stimulates the proliferation of epithelial cells in the mouse uterus. In contrast, progesterone is inhibitory to this estrogen-mediated proliferation of the luminal and glandular epithelial cells. However, progesterone, alone or in conjunction with estrogen, leads to uterine stromal cell proliferation. The ability of these steroid hormones to regulate uterine cell proliferation depends upon the ability of hormonal stimulation to regulate growth factor communication networks between the uterine stroma and epithelium. An imbalance caused by increased estrogen action and/or decreased progesterone action can result in abnormal endometrial proliferation and endometrial adenocarcinoma. Therefore, elucidating the molecular mechanisms by which the steroid hormones control uterine physiology is important to understanding the pathology of these diseases.[@b4-jcp-18-313]--[@b6-jcp-18-313]

Phosphatase and tensin homologue (*PTEN*) is one of the most frequently mutated tumor suppressor genes in type I endometrioid endometrial carcinomas, approximately 50--80%, and is involved in the control of cell proliferation, differentiation, and apoptosis.[@b7-jcp-18-313],[@b8-jcp-18-313] *PTEN* is completely lost or mutated in about 50% of primary endometrioid endometrial cancer and in at least 20% of endometrial hyperplasia, the precancerous lesions of the endometrium.[@b8-jcp-18-313],[@b9-jcp-18-313] The presence of *PTEN* mutations in hyperplasia suggests that *PTEN* inactivation may occur as an initiating event in endometrial carcinogenesis and is involved in the development of cytologic atypia in hyperplasia.

*PTEN* acts as a negative regulator of phosphoinositide 3-kinases (PI3K) signaling, a regulator of a number of cellular functions through the activation of AKT. Interestingly, the PTEN/PI3K/AKT signaling pathway can also be activated by estrogen, suggesting a complex interaction between these two signaling pathways. Loss of PTEN and subsequent AKT activation resulted in the activation of estrogen receptor-dependent pathways that play an important role in the tumorigenesis of endometrial cancer.[@b8-jcp-18-313],[@b10-jcp-18-313],[@b11-jcp-18-313] Moreover, there are reports that steroid hormones may regulate endometrial PTEN expression helping to protect the balance between proliferative and anti-proliferative actions in normal endometrium.[@b12-jcp-18-313]

In order to understand the effect of steroid hormone on endometrial cancer, we induced endometrial cancer through conditional loss of *Pten* in the mouse uterus (*PR*^*cre*/+^ *Pten^f/f^*, *Pten^d/d^*). To assess the effect of steroid hormone, ovariectomized *Pten^f/f^* and *PR*^*cre*/+^ *Pten^f/f^* mice were treated with vehicle or progesterone over a period of three months. Uterine weight gain was significantly decreased in ovariectomized *PR*^*cre*/+^ *Pten^f/f^* mice treated with vehicle or progesterone compared to intact *PR*^*cre*/+^ *Pten^f/f^* mice. Ovariectomized *PR*^*cre*/+^ *Pten^f/f^* mice treated with vehicle or progesterone exhibited a decreased cancer size compared with intact *PR*^*cre*/+^ *Pten^f/f^* mice. Histological analysis displayed endometrial adenocarcinoma with invasion into the myometrium in intact and ovariectomized *PR*^*cre*/+^ *Pten^f/f^* mice treated with vehicle or progesterone. These results suggest that tumor mass is significantly reduced in the absence of steroid hormones but does not affect cancer progression in *PR*^*cre*/+^ *Pten^f/f^* mice.

MATERIALS AND METHODS
=====================

1.. Animals and tissue collection
---------------------------------

Mice were cared for and used in the designated animal care facility according to the Michigan State University institutional guidelines. All animal procedures were approved by the Institutional Animal Care and Use Committee of Michigan State University. In order to achieve *Pten* ablation, mice with floxed *Pten* (*Pten^f/f^*) were bred to the *PR*^*cre*/+^ mouse.[@b13-jcp-18-313],[@b14-jcp-18-313] As a result of cre recombinase insertion at the progesterone receptor (PR) locus, floxed genes are edited specifically in PR expressing cells, including all compartments of the mouse uterus.[@b14-jcp-18-313],[@b15-jcp-18-313] This model (*PR*^*cre*/+^ *Pten^f/f^*, *Pten^d/d^*) was previously used to ablate *Pten* in the uterus resulting in endometrial adenocarcinoma.[@b16-jcp-18-313]

For the study of steroid hormone dependency on cancer progression in the endometrial cancer mouse model, *Pten^f/f^* mice and *PR*^*cre*/+^ *Pten^f/f^* mice were ovariectomized at two months of age. Two weeks later, ovariectomized mice were treated with one of the following: Vehicle (beeswax), Progesterone (20 mg/pellet), Estrogen (20 μg/pellet) pellets subcutaneously every month over a period of three months (progesterone treatment) or one month (estrogen treatment). Uterine tissues were collected and fixed with 4% (vol/vol) paraformaldehyde and paraffin embedded for histological analysis.

2.. Immunohistochemistry
------------------------

Uterine sections from paraffin-embedded tissue were cut at 5 μm and mounted on silane-coated slides, deparaffinized, and rehydrated in a graded alcohol series. Sections were preincubated with 10% normal goat serum in PBS (pH 7.5) and then incubated with primary antibody diluted in 10% normal goat serum in PBS (pH 7.5) overnight at 4°C at the following dilutions: 1:200 for anti-PR antibody (sc-7208, Santa Cruz Biotech., Santa Cruz, CA), 1:500 for anti-ERα (M-7047, DAKO Corp., Carpinteria, CA), 1:1,000 for anti-phospho-Histone H3 (06--570, Millipore, Billerica, MA) and 1:500 for anti-cleaved Caspase 3 (\#9661, Cell Signaling, Danvers, MA). On the following day, sections were washed in PBS and incubated with a biotinylated secondary antibody (5 μl/ml; Vector Laboratories, Burlingame, CA) for one hour at room temperature. Immunoreactivity was detected using the Vectastain Elite DAB kit (Vector Laboratories, Burlingame, CA). The sections were counterstained with hematoxylin, dehydrated, and mounted. PR, ERα, Phospho-Histone H3 and cleaved Caspase 3 immunostained sections were counted by assessing the percentage of positive cells.

3.. Statistical methods
-----------------------

Analyses were performed using Graphpad (San Diego, CA). Tukey's post hoc multiple comparisons test was used to analyze the differences between multiple groups. P values lower than 0.05 were considered statistically significant.

RESULTS
=======

1.. Diminution of endometrial cancer size by progesterone treatment in PR^cre/+^ Pten^f/f^ mice
-----------------------------------------------------------------------------------------------

Previous studies have shown the role of mutations in *PTEN* and unopposed estrogen stimulation in the pathogenesis of uterine endometrioid carcinoma and recently, *Pten* heterozygous mice (*Pten*^+/−^) treated with estrogen resulted in the increased carcinoma incidence.[@b17-jcp-18-313] In order to determine the role of ovarian steroid hormone in uterine specific Pten ablated mice, (*PR*^*cre*/+^ *Pten^f/f^*, *Pten^d/d^*), first we confirmed the development of endometrial cancer in the *PR*^*cre*/+^ *Pten^f/f^* mice. Similar to previous work,[@b13-jcp-18-313] we also observed the development of endometrial cancer ([Fig. 1B](#f1-jcp-18-313){ref-type="fig"}).

To examine the effect of estrogen on *PR*^*cre*/+^ *Pten^f/f^* mice, we ovariectomized *Pten^f/f^* and *PR*^*cre*/+^ *Pten^f/f^* mice at two months of age and treated with vehicle or estrogen over a period of one month, and then mice were sacrificed at 3.5 months of age (*n*=*5* per treatment per genotype). Ovariectomized estrogen-treated *PR*^*cre*/+^ *Pten^f/f^* mice showed significantly increased uterine weight and gross morphology when compared to *Pten^f/f^* mice as observed in intact *PR*^*cre*/+^ *Pten^f/f^* mice ([Fig. 1A](#f1-jcp-18-313){ref-type="fig"}, [1B](#f1-jcp-18-313){ref-type="fig"}). Histological morphology showed development of endometrial cancer in intact and ovariectomized *PR*^*cre*/+^ *Pten^f/f^* mice treated with estrogen. These results showed that *PR*^*cre*/+^ *Pten^f/f^* mice developed severe endometrial cancer within one month of estrogen treatment compared to intact mice.

Progesterone hormone therapy has been shown to slow cancer cell growth for up to 30% of women who had advanced endometrial cancer.[@b3-jcp-18-313],[@b18-jcp-18-313] Next, we examined the effect of progesterone on endometrial cancer development when *Pten* is mutated. *Pten^f/f^* and *PR*^*cre*/+^ *Pten^f/f^* mice were overiectomized at two month of age and treated with vehicle or progesterone over a period of three months (*n*=*5* per treatment per genotype). Mice were sacrificed at 5.5 months of age. Uterine weight, gross and histological morphology was examined ([Fig. 2](#f2-jcp-18-313){ref-type="fig"}). Both ovariectomized vehicle and progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice showed significantly decreased uterine weight when compared to intact *PR*^*cre*/+^ *Pten^f/f^* mice ([Fig. 2A](#f2-jcp-18-313){ref-type="fig"}). Gross morphology of ovariectomized vehicle and P4 treated *PR*^*cre*/+^ *Pten^f/f^* mice displayed dramatically reduced development of endometrial cancer compared to intact *PR*^*cre*/+^ *Pten^f/f^* mice ([Fig. 2B](#f2-jcp-18-313){ref-type="fig"}). Histological analysis showed endometrial adenocarcinoma with invasion into the myometrium in all groups indicating that endometrial cancer progression is not affected. Interestingly, reduction of endometrial cancer size was observed in ovariectomized vehicle and progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice ([Fig. 2C](#f2-jcp-18-313){ref-type="fig"}). These results suggest that tumor mass is significantly reduced in the absence of estrogen but does not affect cancer metastasis in the *Pten* ablated mouse uterus.

2.. Decreased proliferation in ovariectomized PR^cre/+^ Pten^f/f^ mice after P4 treatment
-----------------------------------------------------------------------------------------

To address whether reduction of tumor mass in *PR*^*cre*/+^ *Pten^f/f^* mice is caused by an alteration in endometrial uterine cell proliferation and/or apoptosis, we performed immunohistochemical analysis for phosphohistone H3, a mitotic marker in the endometrium of intact, ovariectomized vehicle or progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice. Phosphohistone H3 immunostaining was significantly decreased in the endometrial epithelium of ovariectomized progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice compared with other groups, but there are no changes in stromal cells ([Fig. 3A](#f3-jcp-18-313){ref-type="fig"}, [3B](#f3-jcp-18-313){ref-type="fig"}). These results suggest that progesterone suppresses proliferation of uterine epithelial cells in *PR*^*cre*/+^ *Pten^f/f^* mice contributing to reduced tumor mass.

3.. An increase of stromal PR expression in ovariectomized PR^cre/+^ Pten^f/f^ mice after P4 treatment
------------------------------------------------------------------------------------------------------

Expression of PR and ERα have been studied as prognostic factors for endometrial carcinoma.[@b19-jcp-18-313]--[@b23-jcp-18-313] We assessed the expression of PR and ERα by immunohistochemistry in intact, ovariectomized vehicle or progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice. Immunostaining of PR revealed highly increased stormal PR expression in the endometrium of ovariectomized progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice, whereas intact and ovariectomized vehicle treated *PR*^*cre*/+^ *Pten^f/f^* mice showed that a decrease of stromal PR expression ([Fig. 4A](#f4-jcp-18-313){ref-type="fig"}, [4B](#f4-jcp-18-313){ref-type="fig"}). The expression level of ERα was not significantly changed between any groups ([Fig. 4C](#f4-jcp-18-313){ref-type="fig"}, [4D](#f4-jcp-18-313){ref-type="fig"}). This data suggest that progesterone treatment leads to an increase in stromal PR expression in ovariectomized *PR*^*cre*/+^ *Pten^f/f^* mice.

DISCUSSION
==========

Estrogen-dependent endometrioid carcinoma is the most common type of gynecological cancer.[@b6-jcp-18-313],[@b24-jcp-18-313] Numerous studies support that prolonged, unopposed estrogen exposure has been associated with increased incidence of endometrial cancer[@b3-jcp-18-313],[@b25-jcp-18-313] and aberrant activation of the PTEN/PI3K/AKT signaling pathways.[@b26-jcp-18-313] The PTEN/PI3K/AKT signaling pathway can be activated by estrogen.[@b27-jcp-18-313] We used a *PR*^*cre*/+^ *Pten^f/f^* (*Pten^d/d^*) mouse model[@b16-jcp-18-313],[@b28-jcp-18-313] to examine the effect of ovarian steroid hormone in tumorigenesis of endometrial cancer. To understand the effect of estrogen on the endometrial tumorigenesis, *PR*^*cre*/+^ *Pten^f/f^* mice were treated with estrogen for 90 days. Estrogen treatment induced more severe endometrial tumorigenesis compared to control group, thereby indicating its important role in cancer development ([Fig. 1](#f1-jcp-18-313){ref-type="fig"}).

To examine dependency of ovarian steroid hormones on the endometrial tumorigenesis of *Pten* mutation, *PR*^*cre*/+^ *Pten^f/f^* mice were ovariectomized to remove the endogenous steroid hormone. Ovariectomized *PR*^*cre*/+^ *Pten^f/f^* mice showed significantly decreased uterine weight when compared to intact *PR*^*cre*/+^ *Pten^f/f^* mice ([Fig. 2](#f2-jcp-18-313){ref-type="fig"}). The development of endometrial cancer in *PR*^*cre*/+^ *Pten^f/f^* mice is independent of ovarian steroid hormone. Mice with a single deleted *Pten* allele (*Pten*^+/−^) also developed complex atypical hyperplasia and ∼20% developed endometrial cancer.[@b17-jcp-18-313],[@b29-jcp-18-313] These results suggest that the development of endometrial cancer in *Pten* mutation is independent of steroid hormones.

Progesterone is a hormone that antagonizes the growth-promoting properties of estrogen in the uterus.[@b6-jcp-18-313],[@b30-jcp-18-313] Progestin has been used in the conservative endocrine treatment to early endometrial cancer patients in order to preserve their fertility, as well as in palliative treatment to advanced-stage patients.[@b31-jcp-18-313]--[@b34-jcp-18-313] Progesterone therapy prevents the development of endometrial cancer associated with unopposed estrogen by blocking estrogen actions as well as in palliative treatment to advanced-stage patients who are poor surgical candidates.[@b31-jcp-18-313],[@b33-jcp-18-313],[@b34-jcp-18-313] However, more than 30% of patients with progestin treatment did not respond to progestin due to de novo or acquired progestin resistance.[@b33-jcp-18-313],[@b35-jcp-18-313]--[@b38-jcp-18-313] The mechanism of progestin resistance is still unknown. P4 treatment showed reduction of endometrial cancer size ([Fig. 2B](#f2-jcp-18-313){ref-type="fig"}) but did not suppress metastasis of endometrial adenocarcinoma into the myometrium ([Fig. 2C](#f2-jcp-18-313){ref-type="fig"}). These results suggest that tumor mass is significantly reduced in the absence of estrogen but does not affect cancer metastasis in the *Pten* ablated mouse uterus.

Estrogen stimulates proliferation of epithelial cells in the mouse uterus.[@b6-jcp-18-313],[@b30-jcp-18-313] In contrast, progesterone inhibits the estrogen-mediated proliferation of the luminal and glandular epithelial cells.[@b5-jcp-18-313],[@b30-jcp-18-313],[@b39-jcp-18-313] It is reported that endometrial cancer is an estrogen-dependent disease and that progesterone therapy has been used successfully to slow the growth of endometrial tumors in women by its inhibitory effects on estrogen action.[@b31-jcp-18-313]--[@b34-jcp-18-313],[@b40-jcp-18-313] Reduction of tumor mass was found in ovariectomized vehicle and progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice. Interestingly, endometrial cancer progression is not affected in ovariectomized vehicle and progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice ([Fig. 2](#f2-jcp-18-313){ref-type="fig"}). This indicates that the progression of endometrial cancer can be associated with *Pten* mutation and the correlation between the expression of PTEN and clinical status of endometrial cancer patients should be evaluated. Even though ovariectomized vehicle and progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice exhibited endometrial cancer progression, we observed an alteration in endometrial uterine cell proliferation. Proliferation is significantly decreased in ovariectomized vehicle and progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice compared to intact *PR*^*cre*/+^ *Pten^f/f^* in epithelial ([Fig. 3](#f3-jcp-18-313){ref-type="fig"}). Despite clinical use of progesterone, the antitumor mechanisms for progesterone therapy is still unknown. Our results showed that progesterone can induce decreased cellular proliferation during endometrial tumorigenesis.

Expression of PR and ERα have been reported as prognostic factors for endometrial carcinoma.[@b19-jcp-18-313]--[@b23-jcp-18-313] Decreased expression of *PTEN* gene and expression of PR and ERα occurs in the majority of patients with endometrial cancer.[@b41-jcp-18-313] Expression of progesterone receptor (PR) is positively correlated with a good prognosis and response to progesterone treatment.[@b42-jcp-18-313] However, more than 30% of patients with progesterone treatment did not respond to progesterone due to de novo or acquired progesterone resistance.[@b33-jcp-18-313],[@b35-jcp-18-313]--[@b38-jcp-18-313] In this study, we addressed that the expression of stromal PR was significantly increased in ovariectomized progesterone treated *PR*^*cre*/+^ *Pten^f/f^* mice, whereas highly decreased in intact and ovariectomized vehicle treated *PR*^*cre*/+^ *Pten^f/f^* mice. The level of ERα was not changed among the groups ([Fig. 3](#f3-jcp-18-313){ref-type="fig"}). It is studied that progesterone inhibits the proliferation of endometrial epithelial cells via PR in stromal cells by blocking the production of mitogenic mediators in the stroma.[@b43-jcp-18-313],[@b44-jcp-18-313] This suggest that the induction of stromal PR by P4 treatment in ovariectomized *PR*^*cre*/+^ *Pten^f/f^* mice may play a role in the reduction of tumor mass via regulating epithelial cell proliferation.

In conclusion, our results show that the steroid hormones intervene in the endometrial tumorigenesis of *PR*^*cre*/+^ *Pten^f/f^* mice. PTEN/PI3K/AKT signal pathway is aberrantly regulated in a wide range of human tumors making them excellent candidates for selective anticancer therapies. However, the relationship between PTEN/PI3K/AKT and steroid hormone signaling pathways is not well known. Based on the extensive crosstalk between PTEN/PI3K/AKT and steroid hormone signaling, drug combination approaches targeting both pathways would seem to be a rational clinical strategy to improve the efficacy of endocrine therapies. This analysis will identify potential therapeutic targets for the treatment of endometrial cancer. Our study will allow the development of future PTEN/PI3K/AKT and steroid hormone signaling- targeted therapeutic tools to attenuate the progress of endometrial cancer.
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![Estrogen dependent formation of endometrial cancer in *PR*^*cre*+^ *Pten^f/f^* mice. (A) The ratio of uterine weight to body weight in intact and ovariectomized E2 treated *PR*^*cre*+^ *Pten^f/f^* mice (OVX E2). The results represent the mean±SEM. \*P\< 0.05, ^\*\*\*^P\<0.001. (B) The uterine gross morphology of intact and ovariectomized E2 treated *Pten^f/f^* mice (OVX E2) (a, b) and *PR*^*cre*+^ *Pten^f/f^* mice (c, d). (C) Estrogen (E2) treatment induces endometrial cancer development in *Pten* ablated mice uterus. Hematoxylin and eosin staining of intact and ovariectomized E2 treated *Pten^f/f^* mice (OVX E2) (a, b) and *PR*^*cre*+^ *Pten^f/f^* mice (c, d).](jcp-18-313f1){#f1-jcp-18-313}

![Ovariectomized vehicle (OVX Veh) and P4 treated *PR*^*cre*+^ *Pten^f/f^* mice (OVX P4) show a decrease uterine weight compared with intact. (A) The ratio of uterine weight to body weight in intact, ovariectomized vehicle (OVX Veh) and P4 treated *PR*^*cre*+^ *Pten^f/f^* mice (OVX P4). The results represent the mean±SEM. \*\*P\<0.01, ^\*\*\*^P\<0.001. (B) The uterine gross morphology of intact, ovariectomized vehicle (OVX Veh) and P4 treated *PR*^*cre*+^ *Pten^f/f^* mice (OVX P4) (a--c) and *PR*^*cre*+^ *Pten^f/f^* mice (d--f). (C) Hematoxylin and eosin staining of intact, ovariectomized vehicle (OVX Veh) and P4 treated *PR*^*cre*+^ *Pten^f/f^* mice (OVX P4) (a--c) and *PR*^*cre*+^ *Pten^f/f^* mice (d, e and f for low magnification; g, h and i for high magnification).](jcp-18-313f2){#f2-jcp-18-313}

![The regulation of proliferation and apoptosis in *Pten* ablated mice uterus after P4 treatment. (A) Immunostaining for phospho-histone H3 in intact, ovariectomized vehicle (OVX Veh) and P4 treated *PR*^*cre*+^ *Pten^f/f^* mice (OVX P4) (a--c) and *PR*^*cre*+^ *Pten^f/f^* mice (d--f). (B) Quantification of phospho-histone H3 positive cells in epithelial cells. The results represent the mean±SEM. ^\*^P\< 0.05, ^\*\*\*^P\<0.001.](jcp-18-313f3){#f3-jcp-18-313}

![The expression of PR is recovered in *PR*^*cre*+^ *Pten^f/f^* mice after P4 treatment. (A) Immunohistochemical analysis of PR in the uteri of intact, ovariectomized vehicle (OVX Veh) and P4 treated *PR*^*cre*+^ *Pten^f/f^* mice (OVX P4) (a--c) and *PR*^*cre*+^ *Pten^f/f^* mice (d--f). (B) Quantification of PR positive cells in stromal cells. The results represent the mean±SEM. \*P\<0.05, \*\*P\<0.01. (C) Immunohistochemical analysis of ERα in the uteri of intact, ovariectomized vehicle (OVX Veh) and P4 treated *PR*^*cre*+^ *Pten^f/f^* mice (OVX P4) (a--c) and *PR*^*cre*+^ *Pten^f/f^* mice (d--f). (D) Quantification of PR positive cells in stromal cells.](jcp-18-313f4){#f4-jcp-18-313}
